New Discoveries and Honors in Cancer Research

Read the latest cancer research and recognition from the members of the Damon Runyon scientific circle.
March 18, 2016
New compound may be effective against resistant leukemia

Douglas K. Graham, MD, PhD (Damon Runyon Clinical Investigator ’07-’12), of Emory University School of Medicine, Atlanta, and colleagues, reported that a novel compound called MRX-2843 has shown promise in preclinical studies; it blocked the growth of acute myeloid leukemia (AML) cells, led to a significant level of cancer cell death and more than doubled the median days of survival in laboratory models with a drug-resistant form of the disease. MRX-2843 is effective at targeting cancer cells with activated MERTK protein. They hope to obtain FDA approval to test the promising drug in adults and children with AML. The findings were published in the journal JCI Insight.